Navigation Links
Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
Date:4/29/2009

New Screening Test Will Focus on 4.3 Million Annual U.S. Birth Market

SAN DIEGO, April 29 /PRNewswire-FirstCall/ -- Bio-Matrix Scientific Group Inc. (OTC Bulletin Board: BMSN) and Entest BioMedical Inc., BMSN's wholly-owned subsidiary, today announced that a contract has been signed with Dr. Brian Koos, a professor of Obstetrics and Gynecology at the David Geffen School of Medicine at UCLA for the development, refinement, and validation of a screening test for gestational diabetes, a glucose intolerance in pregnant women. Dr. Koos is the developer of a screening test for gestational diabetes licensed to Entest BioMedical by UCLA. The screening test mitigates the lengthy process of diagnosing gestational diabetes and would allow for faster treatment of the disease. Entest is the exclusive licensee for Dr. Koos' gestational diabetes screening test. Both companies stated that their goal is to develop a large scale sampling for validation of the screening test with Food and Drug Administration. The gestational diabetes screening test would be marketed to hospitals and medical clinics. The U.S. Dept. of Health and Human Services recently reported that there are approximately 4.3 million live births in the U.S.

According to Dr. Koos, "There is a very large potential market for our screening test. Gestational diabetes is diabetes that is found for the first time when a woman is pregnant. Out of every 100 pregnant women in the U.S., three to eight get gestational diabetes. Diabetes means your blood glucose (or blood sugar) is too high. The body uses glucose for energy, but too much glucose in the blood can be harmful. An additional concern is that untreated or uncontrolled gestational diabetes can result in serious problems for your baby, such as being born very large and with extra fat. Such large infants are predisposed to birth injury and to obesity later in life. This non-invasive screening test for gestational diabetes, which is very reliable, is highly accurate in identifying women with gestational diabetes."

About Bio-Matrix Scientific Group Inc.:

Bio-Matrix Scientific Group Inc. (OTCBB: BMSN) is a San Diego, California based biotechnology research and development company with a 15,000 square foot facility that houses two secure cryogenic stem cell banks, three research laboratories, aseptic cellular/tissue class 10,000/100 processing lab, hematology, microbiology and flow cytometry laboratories.

About Entest BioMedical Inc.:

Entest BioMedical Inc. is a wholly owned subsidiary of Bio-Matrix Scientific Group Inc. The Company is involved with the development of testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer:

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.


'/>"/>
SOURCE Bio-Matrix Scientific Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
2. Thomson Scientific Predicts Nobel Laureates
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. Thomson Scientific Announces BONDplus for Biological Researchers
5. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
6. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
7. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
8. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
9. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
10. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
11. Delta Dental Plans Association Forms National Scientific Advisory Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... ... NexTec Group has been selected as a member of the Bob Scott’s VAR ... field of midmarket financial software. , Members of the VAR Stars were selected based ... on revenue and those firms chosen represent a wide range of size and many ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... Outreach is a program that strives to better communities around the world by ... community. It also provides the opportunity for team members to become involved in ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation ... achieved accreditation for its specialty care services. Albertsons Companies is the largest ... care service for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication ...
(Date:1/15/2017)... Santa Rosa, CA (PRWEB) , ... January 15, ... ... to nominate their choice of best physicians in eight Bay Area counties for ... selected by the healthcare research company managing the award process. Results were announced ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock ... Pennsylvania. As construction wraps up on the 14,000+ square foot climbing gym, the owners ... location, including three in New Jersey and two in New York. With this being ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... 2017 Eli Lilly and Company (NYSE: ... INCY ) announced today that the U.S. Food and ... the new drug application (NDA) for investigational baricitinib, a ... severe rheumatoid arthritis (RA). The NDA for baricitinib was ... The FDA extended the action date to allow time ...
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
Breaking Medicine Technology: